Download PDF
CC BY-NC-ND 4.0 · Asian Journal of Oncology 2022; 08(03): 172-174
DOI: 10.1055/s-0042-1750793
Case Report

A Case of Plasma Cell Myeloma with Multilobated and Monocytoid Morphology

Sneha Kakoty
1   Department of Oncopathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India
,
Anurag Saha
1   Department of Oncopathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India
,
Torsha Jana
1   Department of Oncopathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India
,
Jyoti Sawhney
1   Department of Oncopathology, The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Plasma cell myeloma (PCM) accounts for approximately 1% of malignant tumors and 10 to 15% of hematological neoplasms. It is a malignant disease characterized by abnormal proliferation of plasma cells and monoclonal immunoglobulins or free light chains (FLCs). There are many morphological variations of the myeloma plasma cells which include mature, immature, plasmablastic, and pleomorphic types. Here, we report a rare presentation of PCM with normal serum protein electrophoresis but elevated serum FLCs and having convoluted, multilobated, and monocytoid morphology. This type of morphology is related to an aggressive clinical course and resistance to conventional chemotherapy. Moreover, absence of M protein in serum/urine electrophoresis does not rule out the diagnosis of PCM and serum FLC assays plays an important role in this kind of scenarios.

Keywords

light chain myeloma - monocytoid - multilobated


Publication History

Article published online:
01 July 2022

© 2022. Spring Hope Cancer Foundation & Young Oncologist Group of Asia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sheik N, Variganji SK, Inugati VR. et al. Clinico-hematological profile of multiple myeloma in a teaching hospital - a 2 year study. IP Arch Cytol Histopathol Res 2019; 4 (04) 305-309
    Google Scholar
  • 2 Elkins BN. Neoplasia. In: Kaplan LA, Pesce AJ. eds. Clinical Chemistry: Theory, Analysis, Correlation. 5th ed.. Missouri: Mosby Elsevier; 2010: 1051-1067
    Google Scholar
  • 3 Swerdlow SH, Campo E, Harris NL. et al. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. Revised. 4th ed.. Lyon, France: IARC Press; 2017
    Google Scholar
  • 4 Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97 (09) 2900-2902
    CrossrefPubMedGoogle Scholar
  • 5 Zhang JJ, Sun WJ, Huang ZX. et al. Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol 2014; 12: 234
    CrossrefPubMedGoogle Scholar
  • 6 Seili-Bekafigo I, Valković T, Babarović E, Duletić-Načinović A, Jonjić N. Myeloma cell morphology and morphometry in correlation with clinical stages and survival. Diagn Cytopathol 2013; 41 (11) 947-954
    CrossrefPubMedGoogle Scholar
  • 7 Erkut N, Çobanoğlu Ü, Sönmez M. Multiple myeloma with multilobated plasma cell nuclei. Turk J Haematol 2011; 28 (02) 158-159
    CrossrefPubMedGoogle Scholar
  • 8 Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23 (26) 6339-6344
    CrossrefPubMedGoogle Scholar